Hot or Not, Stock Market Edition: 11/06/2026

Happy Friday. Here’s what the Zen Ratings are testing and tossing out today:

• Hot: Semiconductor test equipment maker FormFactor (FORM) earns A grade for Sentiment as AI testing demand builds; logistics player ArcBest (ARCB) topped Q3 estimates and sits #1 in trucking
• Not: Preclinical biotech Spyre Therapeutics (SYRE) carries an $8.75 billion valuation on zero revenue; casino operator MGM Resorts (MGM) missed on Vegas weakness

P.S. Want more hot stocks? Check out our roundup of 4 Stocks to Buy Heavy in November 2026.

A note from our sponsors...

America's Economist Explains This Stock Market in Three Words

Something strange is happening in the stock market. Dr. Mark Skousen, the economist who called the '95 tech boom and the 2009 bottom, has boiled it down to three words. And if he's right, what happens next could make or break your retirement.

Watch the one move he says to make now – free, right here.

🔥 HOT: Semiconductor testing specialist FormFactor (FORM) is building capacity for one of AI’s less obvious bottlenecks: Testing advanced chips and high-bandwidth memory. The latest quarter beat on earnings and revenue, margins have surged, and a new factory plus a Teradyne partnership should help meet rising demand. Shares recently got hit by an AI-policy scare, but analysts remain bullish. For investors, that pullback could offer a way into an AI supply-chain business whose earnings are still accelerating.

FORM has a Zen Rating of A, a Strong Buy recommendation. The Component Grades help explain why the recent selloff has not broken the case: Sentiment earns an A, while Growth and Financials receive B grades. That says forward expectations remain strong and the underlying business is improving despite the volatile share price. Bottom line: AI testing demand is translating into better earnings, while the recent pullback may have created a more interesting entry point.

🥶 NOT: Preclinical biotech Spyre Therapeutics (SYRE) has promising inflammatory-bowel-disease science, but investors are already paying as though much of that promise becomes reality. The company generates no revenue, is expected to stay that way for years, and recently raised another $350 million as cash burn climbs. Yet the stock has surged several hundred percent from its low. For investors, that creates an uncomfortable setup: enormous expectations with virtually no operating business underneath them.

SYRE has a Zen Rating of D, a Sell recommendation. The Component Grades reinforce that risk: Safety earns an F, while Growth, Sentiment, and Artificial Intelligence receive D grades. Nothing scores above C. That tells us the stock is highly vulnerable if the clinical story disappoints or timelines slip. Bottom line: Spyre’s science may eventually justify the excitement, but today’s valuation leaves investors paying well ahead of the evidence.

🔥 HOT: Logistics provider ArcBest (ARCB) just delivered the kind of quarter freight investors have been waiting for. Earnings and revenue beat estimates, shares rallied on the results, and analysts expect EPS to increase dramatically next year as the freight cycle improves. For investors, the attraction is that this looks like the beginning of an earnings recovery rather than the end of one.

ARCB was also recently upgraded to a Zen Rating of B, a Buy recommendation, suggesting the rebound has a solid foundation. The Component Grades support the case: Safety, Growth, and Financials all earn B grades, with nothing below C. That suggests earnings are improving without the model flagging unusual financial or business risk. Bottom line: ArcBest is already showing signs of a freight recovery, and the next leg could come from a sharp rebound in profits.

Note: Looking for more under-the-radar winners? Check this out.

🥶 NOT: Casino operator MGM Resorts (MGM) is running into weakness at the heart of its business. The latest quarter missed on earnings and revenue as Las Vegas room rates softened, and analysts expect earnings to decline rather than recover. Heavy debt makes that slowdown harder to shrug off. For investors, the danger is mistaking a low earnings multiple for a bargain when the earnings themselves are moving backward.

MGM has a Zen Rating of D, a Sell recommendation. The Component Grades give that concern more context: Sentiment earns an F, while Growth and Momentum receive D grades. That means analyst expectations are deteriorating, earnings growth is weak, and the stock trend offers little support. Bottom line: BetMGM may be growing, but weakness on the Strip and shrinking earnings make MGM look more like a value trap than a turnaround.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.